wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACE
Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACE
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
P2860
Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
76e671189a8103494b0572666a849a6d6439a6bc
P2860
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.